Claims
- 1. A composition for the topical treatment of a dermatological condition, comprising:
- (a) 1,25(OH).sub.2 D.sub.3 or an analog thereof, or a mixture thereof; and (b) an RXR ligand or a precursor of an RXR ligand or a mixture thereof,
- wherein the combined amount of said 1,25(OH).sub.2 D.sub.3 and said analog and said mixture thereof in said composition is ineffective alone for said treatment, and which combined amount is effective in combination with said RXR ligand or precursor or mixture thereof.
- 2. The composition of claim 1, wherein said RXR ligand is selected from the group consisting of retinoic acid and precursors thereof.
- 3. The composition of claim 2, wherein the retinoid is 9-cis-retinoic acid.
- 4. The composition of claim 2, wherein the precursor is all trans-retinoic acid.
- 5. The composition of claim 1, further comprising a 24-hydroxylase inhibitor in addition to said RXR ligand.
- 6. The composition of claim 5, wherein the 24-hydroxylase inhibitor is ketoconazole.
- 7. The composition of claim 1, wherein the precursor is all trans retinoic acid, and the 24-hydroxylase inhibitor is ketoconazole.
- 8. The composition of claim 1, comprising about 0.002% to about 0.05% by weight of 1,25(OH).sub.2 D.sub.3.
- 9. The composition of claim 1, comprising about 0.025% to about 0.1% by weight of RXR ligand.
- 10. A composition for the topical treatment of a dermatological condition, comprising:
- (a) 1,25(OH).sub.2 D.sub.3, an analog thereof, or a mixture thereof, which is metabolized by 24-hydroxylase; and (b) a 24-hydroxylase inhibitor or a mixture thereof;
- wherein the combined amount of said 1,25(OH).sub.2 D.sub.3 and said analog and mixture thereof in said composition is ineffective alone for said treatment, and which combined amount is effective in combination with said 24-hydroxylase inhibitor or said mixture thereof.
- 11. The composition of claim 10, wherein the 24-hydroxylase inhibitor is ketoconazole.
- 12. The composition of claim 10, further comprising an RXR ligand.
- 13. The composition of claim 12, wherein the RXR ligand is all-trans retinoic acid or 9-cis retinoic acid.
- 14. The composition of claim 13, wherein the 24-hydroxylase inhibitor is ketoconazole.
- 15. The composition of claim 10, comprising about 0.002% to about 0.05% by weight of 1,25(OH).sub.2 D.sub.3.
- 16. The composition of claim 1, comprising about 1% to about 3% by weight of RXR ligand.
Parent Case Info
This application is a division of Ser. No. 08/832,865 filed Apr. 4, 1997. This application claims priority from provisional application Ser. No. 60/015,145, filed Apr. 5, 1996, the disclosure of which is incorporated herein by reference.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4569935 |
Rosenberg et al. |
Feb 1986 |
|
Non-Patent Literature Citations (2)
Entry |
Spearman et al., Brit. J. Dermatology, 40(5) 553-60 (abstract), 1974. |
Lutzow-Horn et al., Experimental Dermatology 2(3), 113-20 (Denmark) (abstract), 1993. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
832865 |
Apr 1997 |
|